|
|
||||||||
Papers In Press, published online ahead of print May 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INSERM U525, Faculté de Médecine Pitié-Salpétrière, Paris 75634
Corresponding Author: ninio{at}chups.jussieu.fr
Inflammation underlies both onset and perpetuation of atherosclerosis. Plasma lipoproteins transport the PAF-acetylhydrolase (PAF-AH) with potentially anti-inflammatory activities. Our aim was to determine whether PAF-AH activity was associated with inflammatory markers and with coronary artery disease (CAD). PAF-AH activity and a panel of inflammatory mediators were measured in plasma of 496 patients with CAD and in 477 controls; 276 patients presented with stable angina pectoris and 220 with acute coronary syndrome. Individuals within the highest quartile of PAF-AH activity had a 1.8-fold increase in CAD risk (95% CI 1.01 to 3.2, P=0.048) compared to those in the first quartile (adjusted for clinical and metabolic factors). When excluding individuals receiving statin and ACE-inhibitor medication, individuals within the highest quartile of PAF-AH activity revealed a 3.9-fold increase in CAD risk (95%CI 2.0 to 7.7, P<0.0001). In these subjects, the plasma PAF-AH activity raised gradually in stable angina and in acute coronary syndrome both in men (P<0.0001) and in women (P<0.001), as compared to controls. No correlation was found between PAF-AH levels and those of common markers of inflammation. This study and the previous ones raises an important issue whether PAF-AH is simply a marker of risk or it directly promotes atherosclerosis.
Revised on April 22, 2003
Accepted on April 22, 2003
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
E. S. Brilakis, A. Khera, B. Saeed, S. Banerjee, D. K. McGuire, S. A. Murphy, and J. A. de Lemos Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings from the Dallas Heart Study Clin. Chem., December 1, 2008; 54(12): 1975 - 1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Kim, Y. J. Hyun, Y. Jang, B. K. Lee, J. S. Chae, S. E. Kim, H. Y. Yeo, T.-S. Jeong, D. W. Jeon, and J. H. Lee Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study Am. J. Clinical Nutrition, September 1, 2008; 88(3): 630 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Sabatine, D. A. Morrow, M. O'Donoghue, K. A. Jablonksi, M. M. Rice, S. Solomon, Y. Rosenberg, M. J. Domanski, J. Hsia, and for the PEACE Investigators Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2463 - 2469. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Winkler, M. M. Hoffmann, B. R. Winkelmann, I. Friedrich, G. Schafer, U. Seelhorst, B. Wellnitz, H. Wieland, B. O. Boehm, and W. Marz Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study) Clin. Chem., August 1, 2007; 53(8): 1440 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. MacRitchie, A. A. Gardner, S. M. Prescott, and D. M. Stafforini Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation FASEB J, April 1, 2007; 21(4): 1164 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Oldgren, S. K. James, A. Siegbahn, and L. Wallentin Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients Eur. Heart J., March 2, 2007; 28(6): 699 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Kolodgie, A. P. Burke, K. S. Skorija, E. Ladich, R. Kutys, A. T. Makuria, and R. Virmani Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2523 - 2529. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Jang, O. Y. Kim, S. J. Koh, J. S. Chae, Y. G. Ko, J. Y. Kim, H. Cho, T.-S. Jeong, W. S. Lee, J. M. Ordovas, et al. The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3521 - 3527. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zalewski, J. J. Nelson, L. Hegg, and C. Macphee Lp-PLA2: A New Kid on the Block Clin. Chem., September 1, 2006; 52(9): 1645 - 1650. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kardys, H.-H. S. Oei, I. M. van der Meer, A. Hofman, M. M.B. Breteler, and J. C.M. Witteman Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary Atherosclerosis: The Rotterdam Study Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 631 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sudhir Lipoprotein-Associated Phospholipase A2, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3100 - 3105. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Winkler, B. R. Winkelmann, H. Scharnagl, M. M. Hoffmann, A. B. Grawitz, M. Nauck, B. O. Bohm, and W. Marz Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study Circulation, March 1, 2005; 111(8): 980 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Iribarren, M. D. Gross, J. A. Darbinian, D. R. Jacobs Jr, S. Sidney, and C. M. Loria Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 216 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Verreth, D. De Keyzer, M. Pelat, P. Verhamme, J. Ganame, J. K. Bielicki, A. Mertens, R. Quarck, N. Benhabiles, G. Marguerie, et al. Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-{alpha} and Peroxisome Proliferator-Activated Receptor-{gamma} Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice Circulation, November 16, 2004; 110(20): 3259 - 3269. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ninio, D. Tregouet, J.-L. Carrier, D. Stengel, C. Bickel, C. Perret, H. J. Rupprecht, F. Cambien, S. Blankenberg, and L. Tiret Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease Hum. Mol. Genet., July 1, 2004; 13(13): 1341 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Tambaki, E. Rizos, V. Tsimihodimos, A. D. Tselepis, and M. Elisaf Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 91 - 95. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |